WASHINGTON--(BUSINESS WIRE)--LFA – Research scientists and physicians – including scientific thought leaders from university centers, pharmaceutical and biotechnology industries, the National Institutes of Health, U.S. Food and Drug Administration, and other government agencies – will address two important gaps impeding approval of new treatments for the autoimmune disease lupus during the Lupus Foundation of America’s (LFA) 2nd International Flare Conference June 5 and 6 in suburban Washington, DC. These experts will discuss modifications to tools used to monitor disease progression and how lupus patients respond to treatment. They also will work to develop a consensus definition of a lupus flare, which is an increase in disease activity.
